Alexion, 澳门在线赌城娱乐 罕见的疾病, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer 公司. (辉瑞).
These new resources build on the combined capabilities of Alexion and 澳门在线赌城娱乐 in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. 另外, several of the Pfizer employees associated with the portfolio will join Alexion as employees.
Financial considerations
Alexion has purchased and licenced the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales.
笔记
Alexion
Alexion, 澳门在线赌城娱乐 罕见的疾病, is the group within 澳门在线赌城娱乐 focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, 公司. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, 发展 and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its 发展 efforts on haematology, 肾脏学, 神经学, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, and BioPharmaceuticals, including Cardiovascular, 肾 & Metabolism, and 呼吸 & 免疫学. Based in 剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com and follow the Company on social media @澳门在线赌城娱乐.
联系人
For details on how to contact the Investor Relations Team, please click 在这里. For 媒体 contacts, click 在这里.
艾德里安·坎普
Company Secretary
澳门在线赌城娱乐 PLC